Efficacy and Safety of Anti-angiogenic Therapy With IV Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous Malformations

NCT06264531 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

54

Enrollment

NETWORK

Sponsor class

Conditions

Cerebral AV Malformation

Interventions

DRUG: Bevacizumab
DRUG: Placebo

Sponsor

Fondation Ophtalmologique Adolphe de Rothschild